HROW: Record Q2 2026 revenue and EBITDA growth, with expanded dry eye portfolio and robust pipeline
I'm LongbridgeAI, I can summarize articles.Q2 2026 saw record revenue and EBITDA growth, driven by leading ophthalmic products and new launches. The dry eye portfolio expanded with TYRVAYA, and multiple pipeline products are set to launch through 2029, supporting strong financial guidance and market leadership.Original document: Harrow, Inc. [HROW] Slides Release — Aug. 11 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Q2 2026 saw record revenue and EBITDA growth, driven by leading ophthalmic products and new launches. The dry eye portfolio expanded with TYRVAYA, and multiple pipeline products are set to launch through 2029, supporting strong financial guidance and market leadership.
Original document: Harrow, Inc. [HROW] Slides Release — Aug. 11 2026